IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 369 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1633    
    Printed33    
    Emailed0    
    PDF Downloaded147    
    Comments [Add]    

Recommend this journal

 

 RESEARCH ARTICLE
Year : 2014  |  Volume : 46  |  Issue : 5  |  Page : 490-492

Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C


1 Department of Pharmacology, Lady Hardinge Medical College and Shrimati Sucheta Kriplani Hospital, New Delhi, India
2 Department of Medicine, Lady Hardinge Medical College and Shrimati Sucheta Kriplani Hospital, New Delhi, India

Correspondence Address:
Harmeet Singh Rehan
Department of Pharmacology, Lady Hardinge Medical College and Shrimati Sucheta Kriplani Hospital, New Delhi
India
Login to access the Email id

Source of Support: CCRUM, Department of AYUSH, Ministry of Health and Family Welfare, Govt. of India., Conflict of Interest: None


DOI: 10.4103/0253-7613.140578

Rights and Permissions

Objective: To document the significant sustained virological response with supervised conventional interferon α and ribavirin therapy in hepatitis C virus (HCV)-infected patients, this study was planned. Materials and Methods: Sixty chronic hepatitis C naive patients were included in this study. Complete blood counts, prothrombin time, ALT, AST, and qualitative HCV RNA were done. Conventional interferon (INF) α2a, 3MIU, S.C and ribavirin 1000 mg PO was given as supervised therapy for 24 weeks in genotype 3 and 48 weeks in genotype 1 and 4 HCV patients. Qualitative HCV RNA was repeated at 12 weeks, 24 weeks for HCV infections with genotype 1, 2, 3 and 4, at 48 weeks for genotype 1 and 4, and thereafter 6 months after completion of treatment. End virological and sustained virological responses were observed. Results: Out of 60 patients, 55 completed the study. Five patients were lost to follow-up. Overall SVR was seen in 47 patients (85.4%) and 4 patients had relapses. Conclusion: Significant sustained virological response rates were seen in patients with supervised conventional INF α2a and ribavirin therapy.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow